Navigation Links
Deflazacort in Duchenne Muscular Dystrophy
Date:3/24/2016

LONDON, March 24, 2016 /PRNewswire/ --

US Neurology, the peer-reviewed journal, has published an article summarizing the benefits and risks of deflazacort in Duchenne muscular dystrophy.

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO)

Duchenne muscular dystrophy (DMD) is a devastating disorder that is the most common and severe form of childhood onset muscular dystrophy. While guidelines exist that promote a multidisciplinary approach to treatment of DMD, surveys have identified inconsistent adherence to the recommendations. This is particularly highlighted by the variability in the prescriptive habits of corticosteroids, which have a long history of literature supporting their use in DMD. Relatively recent publications have uncovered differences between countries in the prescription patterns of steroid regimens. Currently, treatment recommendations lack comparative data on the efficacy and safety of alternative dosing regimens of corticosteroids. New research is being conducted to help understand the benefits and risks of the most commonly used glucocorticoid regimens in DMD. Deflazacort is a glucocorticoid corticosteroid that is currently seeking approval in the U.S. This article summarizes the relevant published literature on deflazacort to help inform DMD-treating physicians on its impact on the disease.

The full peer-reviewed, open-access article is available here:

href="http://doi.org/10.17925/USN.2016.12.01.17" rel="nofollow">http://doi.org/10.17925/USN.2016.12.01.12

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishes US Neurology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

For inquires please contact:
Carla Denaro - Managing Editor
+44 (0) 207 193 6093
managingeditor@touchmedicalmedia.com

Providing practical opinion to support best practice for busy healthcare professionals.



'/>"/>
SOURCE Touch Medical Media
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. DART Therapeutics Initiates Study of HT-100 For Duchenne Muscular Dystrophy
2. New Evidence Published in Muscle and Nerve on Measuring 6-Minute Walk Distance in Duchenne Muscular Dystrophy
3. PPMD to Lead Duchenne Community in Developing Draft Guidance to Accelerate Drug Development and FDA Review
4. PTC Therapeutics Completes Enrollment of Landmark Trial in Duchenne Muscular Dystrophy
5. Expected Launch of First Disease-Modifying Therapies Through 2023 Will Revolutionize Treatment of Duchenne Muscular Dystrophy
6. ARMGO Pharma and Servier Announce Advancement of Rycal ARM210/S48168 into Clinical Stage Program Targeting Duchenne Muscular Dystrophy
7. Parent Project Muscular Dystrophy and Foundation to Eradicate Duchenne Award $1 Million Grant to ReveraGen BioPharma
8. EspeRares Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy
9. Global Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Market 2015 - Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
10. Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
11. Global Duchenne Muscular Dystrophy Drugs Market 2015-2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International ... promote standards of excellence for the field of eating disorders, announces the opening ... 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):